In Q1 2026, ADMA BIOLOGICS secured FDA approval for an expanded label of ASCENIV, signaling important commercial growth potential. The company also continued its strategic divestiture of three plasma collection centers while maintaining seven, aiming to strengthen capital efficiency and plasma supply resilience. These developments come amid ADMA’s ongoing focus on specialty biologics for immunodeficient patients, supported by proprietary manufacturing processes and targeted market positioning. Risks remain related to manufacturing reliance on third parties, plasma supply variability, and customer concentration, highlighting the need to monitor execution and regulatory milestones closely.